Stephen Worland biography
Dr. Stephen T. Worland Ph.D. serves as Independent Director of the Company. Dr. Worland has served as the President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a company focused on new treatments for cancer. Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for Hepatitis C and cancer, from August 2007 until the company’s acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named Chief Executive Officer, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career in 1988 at Agouron Pharmaceuticals, Inc. and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. Dr. Worland currently serves on the board of directors of Forge Therapeutics, Inc., a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, a position he has held since April 2017. Dr. Worland received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Stephen Worland?
Stephen Worland is 62, he's been the Independent Director of TRACON Pharmaceuticals Inc since 2015. There are 6 older and 8 younger executives at TRACON Pharmaceuticals Inc. The oldest executive at TRACON Pharmaceuticals Inc is William LaRue, 69, who is the Independent Director.
What's Stephen Worland's mailing address?
Stephen's mailing address filed with the SEC is C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO, CA, 92122.
Insiders trading at TRACON Pharmaceuticals Inc
Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.
What does TRACON Pharmaceuticals Inc do?
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
What does TRACON Pharmaceuticals Inc's logo look like?
TRACON Pharmaceuticals Inc executives and stock owners
TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Charles Theuer,
President, Chief Executive Officer, Director -
Dr. Charles P. Theuer M.D., Ph.D.,
CEO, Pres & Director -
Mark Wiggins,
Chief Business Officer -
Mark C. Wiggins M.B.A.,
Chief Bus. Officer -
Scott Brown,
Chief Accounting Officer -
Scott B. Brown CPA, M.S.,
Chief Financial Officer -
Suzy Benedict,
Executive Vice President - Regulatory Affairs -
Stephen Worland,
Independent Director -
J. Rainer Twiford,
Independent Director -
Martin Mattingly,
Independent Director -
William LaRue,
Independent Director -
Saundra Pelletier,
Director -
Bonne Adams,
Executive Vice President - Clinical Operations -
Dr. Brenda Marczi Pharm.D., Pharmd Mba,
Sr. VP of Regulatory Affairs -
Ya Huang,
Exec. Director of Statistical Programming -
Bonne Adams,
Exec. VP of Clinical Operations -
Dr. James L. Freddo,
Chief Medical Officer -
Shahe Garabedian,
Sr. VP & Head of Quality Assurance -
Ravi Nea Partners 14, L.P.N...,
-
Peter W.Nea Partners 14, L....,
-
Scott Dnea Partners 14, L.P...,
-
Patrick Jnea Partners 14, L...,
-
David Mnea Partners 14, L.P...,
-
Anthony A. Jr.Nea Partners ...,
-
Forestnea Partners 14, L.P....,
-
Peter Jnea Partners 14, L.P...,
-
M Jamesnea Partners 14, L.P...,
-
Capital, Llc Ikarian Health...,
-
Patricia L Bitar,
CFO -
Forest Baskett,
10% owner -
Patrick J Kerins,
10% owner -
H Casey Logan,
Chief Business Officer -
Peter J Barris,
10% owner -
M James Barrett,
10% owner -
Anthony A. Jr. Florence,
10% owner -
David M Mott,
10% owner -
Scott D Sandell,
10% owner -
Peter W. Sonsini,
10% owner -
Enterprise Associates 14, L...,
-
Tracon Investment Fund Ii, ...,
-
Paul Edward Walker,
Director -
Ronald L Shazer,
Chief Medical Officer -
Krishna Kittu Kolluri,
10% owner -
Ravi Viswanathan,
10% owner -
Theodore T Wang,
Director -
Cross Border Opportunities ...,
-
Cross Border Opportunities ...,
-
Harry R Weller,
10% owner -
Enterprise Associates 14, L...,
-
Ryan D Drant,
10% owner -
Super V3 Investment Limited...,
10% owner -
Management Inc. Opaleye,
10% owner -
Capital, Llc Ikarian Health...,
-
Lisa Johnson Pratt,
Director -
Carol C. Lam,
Director